Gaithersburg-based MedImmune and Johns Hopkins University have entered into a five-year, $6.5 million research partnership, the company announced Wednesday.
The collaboration will result in joint research projects focused on a broad range of diseases, including cardiovascular and metabolic diseases, oncology, and neuroscience, a spokeswoman for MedImmune said.
“We are excited about the opportunity for our scientists to collaborate with MedImmune researchers to accelerate the development of new therapies to treat a variety of serious diseases such as multiple sclerosis, rheumatoid arthritis, chronic obstructive pulmonary disease and certain types of cancer,” said Dr. Landon King, executive vice dean of Johns Hopkins University School of Medicine, in an emailed news release. “We believe that by working together to leverage the strengths of each organization, we can make significant advances.”
A spokeswoman for MedImmune said the company would contribute at least $5.3 million over the first three years, and that Johns Hopkins would provide the additional resources and project support.
This initiative is one of several regional collaborations by MedImmune.
In September, the company announced a five-year, $6 million research deal with University
of Maryland, Baltimore.